TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33646048

Group type: EXPERIMENTAL
Intervention: Talking head featuring the participant's face
Number of subjects: 228

Group type: COMPARATOR
Intervention: Talking head featuring a stranger's face
Number of subjects: 228

Group type: COMPARATOR
Intervention: Audio-only condition
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Pro-AI pitch playback
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Anti-AI pitch playback
Number of subjects: 228
Study: 33788486

Group type: EXPERIMENTAL
Intervention: Acupuncture + CES
Number of subjects: 200

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 200

Group type: COMPARATOR
Intervention: CES
Number of subjects: 200

Group type: COMPARATOR
Intervention: Medication
Number of subjects: 200
Study: 34047722

Group type: EXPERIMENTAL
Intervention: EGDT with ScvO2 monitoring
Number of subjects: 120

Group type: COMPARATOR
Intervention: EGDT without ScvO2 monitoring
Number of subjects: 120
Study: 33162347

Group type: EXPERIMENTAL
Intervention: Low-frequency vibrations with passive self-ligating brackets
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Low-frequency vibrations with conventional brackets
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (no vibrations)
Number of subjects: 65
Study: 33033062

Group type: EXPERIMENTAL
Intervention: Active acupressure wristbands
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo acupressure wristbands
Number of subjects: 57
Study: 34937085

Group type: EXPERIMENTAL
Intervention: Immediate loading with temporary restorations
Number of subjects: 24

Group type: COMPARATOR
Intervention: Early loading without temporary restorations
Number of subjects: 24
Study: 34990208

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg once every 3 weeks for 35 cycles
Number of subjects: 90
Study: 33119048

Group type: EXPERIMENTAL
Intervention: Toca 511/FC
Number of subjects: 403

Group type: COMPARATOR
Intervention: SOC
Number of subjects: 403
Study: 35835476

Group type: EXPERIMENTAL
Intervention: Mobile app for community health and nutrition workers (CHNWs)
Number of subjects: 9033
Study: 33819508

Group type: EXPERIMENTAL
Intervention: Sublingual Immunotherapy (SLIT)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Subcutaneous Immunotherapy (SCIT)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Subcutaneous Immunotherapy (SCIT) and Sublingual Immunotherapy (SLIT)
Number of subjects: 84
Study: 32590137

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted lopinavir (LPV/r)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 212
Study: 35226081

Group type: EXPERIMENTAL
Intervention: S-1 plus oxaliplatin (SOX) - 130 mg/m2 oxaliplatin on day 1 and 80 to 120 mg/d S-1 orally daily for 2 weeks, 6 cycles (2-4 preoperative and 2-4 postoperative)
Number of subjects: 583

Group type: COMPARATOR
Intervention: Fluorouracil, leucovorin, and oxaliplatin (FOLFOX) - 130 mg/m2 oxaliplatin, 400 mg/m2 fluorouracil, 400 mg/m2 leucovorin, and 2400 mg/m2 fluorouracil as 46-hour infusion on day 1, 6 cycles (2-4 preoperative and 2-4 postoperative)
Number of subjects: 583
Study: 34048876

Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir
Number of subjects: 583

Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir–IFN–β‐1a
Number of subjects: 583

Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Number of subjects: 583

Group type: COMPARATOR
Intervention: control
Number of subjects: 583
Study: 33183666

Group type: EXPERIMENTAL
Intervention: Probiotic intervention (two daily capsules containing Lactobacillus rhamnosus, Saccharomyces cerevisiae, and Bifidobacterium animalis)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo (identical capsule without probiotics)
Number of subjects: 1
Study: 34903380

Group type: EXPERIMENTAL
Intervention: Cis‐RT + CP
Number of subjects: 0

Group type: COMPARATOR
Intervention: CP
Number of subjects: 0
Study: 34324661

Group type: EXPERIMENTAL
Intervention: PD-L1 positive expression (54% of cases)
Number of subjects: 50

Group type: COMPARATOR
Intervention: PD-L1 negative expression (46% of cases)
Number of subjects: 50
Study: 32110986

Group type: EXPERIMENTAL
Intervention: 140 mg of Zynamite® combined with 140 mg of quercetin
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo (728 mg of maltodextrin)
Number of subjects: 57
Study: 36395782

Group type: EXPERIMENTAL
Intervention: Standard of care plus Xpert MTB/RIF Ultra on nasopharyngeal aspirate and stool samples
Number of subjects: 2570

Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 2570

Group type: EXPERIMENTAL
Intervention: Standard of care plus Xpert MTB/RIF Ultra
Number of subjects: 2570
Study: 33423321

Group type: EXPERIMENTAL
Intervention: See‐see partridges (Ammoperdix griseogularis)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pheasants (Phasianus colchicus)
Number of subjects: 20
Study: 35724357

Group type: EXPERIMENTAL
Intervention: octreotide long-acting release (octLAR)
Number of subjects: 51

Group type: COMPARATOR
Intervention: lanreotide
Number of subjects: 51
Study: 33285745

Group type: EXPERIMENTAL
Intervention: Modified Maimendong Decoction (MMD) plus Pirfenidone capsule
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo plus Pirfenidone capsule
Number of subjects: 60
Study: 35267915

Group type: EXPERIMENTAL
Intervention: Liquid diet (LD) group
Number of subjects: 127

Group type: COMPARATOR
Intervention: DPP group
Number of subjects: 127
Study: 33061822

Group type: EXPERIMENTAL
Intervention: Glucagon-like peptide-1 receptor agonist (GLP-1RA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lipid infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy women (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PCOS women
Number of subjects: 0
Study: 35200147

Group type: EXPERIMENTAL
Intervention: BitHabit app with face-to-face group coaching
Number of subjects: 1926

Group type: EXPERIMENTAL
Intervention: BitHabit app alone
Number of subjects: 1926

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 1926
Study: 34380810

Group type: EXPERIMENTAL
Intervention: BioHPP PEEK inlays
Number of subjects: 40

Group type: COMPARATOR
Intervention: Zirconia inlays
Number of subjects: 40
Study: 32718426

Group type: EXPERIMENTAL
Intervention: Computer-assisted instrument guidance (CAIG)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standalone ultrasonography (US)
Number of subjects: 26
Study: 35397798

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide at a dose of 800 μg twice a day plus usual care
Number of subjects: 146

Group type: COMPARATOR
Intervention: Usual care (as needed antipyretics)
Number of subjects: 146
Study: 34644233

Group type: EXPERIMENTAL
Intervention: Pasteurized 100% watermelon juice (360 mL servings, 2 servings per day for 4 weeks)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo beverage (360 mL servings, 2 servings per day for 4 weeks)
Number of subjects: 16
Study: 32691228

Group type: EXPERIMENTAL
Intervention: Intramuscular quadratus lumborum block (QLBi) with 0.4 mL/kg of 0.25% ropivacaine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 36
Study: 33475876

Group type: EXPERIMENTAL
Intervention: Enhanced external counterpulsation (EECP) therapy
Number of subjects: 168

Group type: COMPARATOR
Intervention: Standard medical treatment
Number of subjects: 168
Study: 33938582

Group type: EXPERIMENTAL
Intervention: Parenting Support Program (PSP)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Wait-list (WL) group
Number of subjects: 29
Study: 35107023

Group type: EXPERIMENTAL
Intervention: TLR4 neutralizing antibodies
Number of subjects: 13

Group type: COMPARATOR
Intervention: IgG (control)
Number of subjects: 13
Study: 32958702

Group type: EXPERIMENTAL
Intervention: Lenalidomide concurrent with PCV13 vaccine (arm A)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Lenalidomide sequential to PCV13 vaccine (arm B)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Lenalidomide (both arms)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Lenalidomide
Number of subjects: 49
Study: 35989210

Group type: EXPERIMENTAL
Intervention: Mobile phone intervention for tracking pregnant women
Number of subjects: 248

Group type: COMPARATOR
Intervention: Control group (no mobile phone intervention)
Number of subjects: 248
Study: 33818131

Group type: EXPERIMENTAL
Intervention: Halyard Fluidshield® N95
Number of subjects: 96

Group type: COMPARATOR
Intervention: BSN Medical ProShield® N-95
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: User seal check for both masks
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Both masks
Number of subjects: 96
Study: 32323163

Group type: EXPERIMENTAL
Intervention: Task 2 was IM-compatible
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-task trials (baseline)
Number of subjects: 0
Study: 36345090

Group type: EXPERIMENTAL
Intervention: smTAP
Number of subjects: 65

Group type: COMPARATOR
Intervention: EMST
Number of subjects: 65
Study: 33881673

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser (0.25 W and 0.5 W)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fluoride varnish
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo laser
Number of subjects: 24
Study: 32960073

Group type: EXPERIMENTAL
Intervention: Sexual Health Counseling based on REDI Model
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control Group (no intervention)
Number of subjects: 104
Study: 35384387

Group type: EXPERIMENTAL
Intervention: Micronized progesterone (100 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 32323014

Group type: EXPERIMENTAL
Intervention: MVLSD
Number of subjects: 60

Group type: COMPARATOR
Intervention: CLSD
Number of subjects: 60
Study: 33390353

Group type: EXPERIMENTAL
Intervention: Water Exchange (WE) method
Number of subjects: 450

Group type: COMPARATOR
Intervention: Air-Insufflated (AI) method
Number of subjects: 450
Study: 32583297

Group type: EXPERIMENTAL
Intervention: UDCA 600 mg/day for 6 months
Number of subjects: 190

Group type: COMPARATOR
Intervention: Control group (no UDCA)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: UDCA group
Number of subjects: 190

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 190
Study: 35241243

Group type: EXPERIMENTAL
Intervention: ICD implantation
Number of subjects: 1116

Group type: COMPARATOR
Intervention: Usual clinical care
Number of subjects: 1116
Study: 34935138

Group type: EXPERIMENTAL
Intervention: Transdiagnostic behavior therapy (TBT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Behavioral activation treatment for depression (BATD)
Number of subjects: 40
Study: 32147296

Group type: EXPERIMENTAL
Intervention: SMS reminders only
Number of subjects: 1594

Group type: EXPERIMENTAL
Intervention: SMS reminder and personalised calendar
Number of subjects: 1594

Group type: COMPARATOR
Intervention: Personalised calendar
Number of subjects: 1594

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 1594

Group type: COMPARATOR
Intervention: No intervention (control) after 'No Jab, No Pay' policy
Number of subjects: 1594
Study: 35297288

Group type: EXPERIMENTAL
Intervention: Randomized within-patient controlled trial design
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Experimental condition (non-active bone grafts)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Control condition (standard treatment)
Number of subjects: 1
Study: 32635288

Group type: EXPERIMENTAL
Intervention: Proprioceptive training with the use of virtual reality (VR)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group without training
Number of subjects: 21
Study: 36209764

Group type: EXPERIMENTAL
Intervention: Iberdomide plus dexamethasone (0.3-1.6 mg on days 1-21 of each 28-day cycle; dexamethasone 40 mg once per week, 20 mg if age >75 years)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Iberdomide plus dexamethasone
Number of subjects: 197
Study: 34268887

Group type: EXPERIMENTAL
Intervention: Supervised exercise program
Number of subjects: 37

Group type: COMPARATOR
Intervention: Home exercise program
Number of subjects: 37
Study: 32614825

Group type: EXPERIMENTAL
Intervention: gSOS (polygenic risk score for heel quantitative ultrasound speed of sound)
Number of subjects: 10522

Group type: COMPARATOR
Intervention: Guideline recommendations without genetic prescreening
Number of subjects: 10522
Study: 33977560

Group type: EXPERIMENTAL
Intervention: Varenicline 0.5 mg po b.i.d.
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Varenicline doses (0.25 mg per day, 0.25 mg b.i.d., 0.5 mg b.i.d., and 1.0 mg b.i.d.)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 33
Study: 33167780

Group type: EXPERIMENTAL
Intervention: umeclidinium/vilanterol
Number of subjects: 2425

Group type: COMPARATOR
Intervention: umeclidinium
Number of subjects: 2425

Group type: COMPARATOR
Intervention: salmeterol
Number of subjects: 2425
Study: 36206950

Group type: EXPERIMENTAL
Intervention: Initial invasive management with angiography, revascularization when feasible, and guideline-directed medical therapy (GDMT)
Number of subjects: 5956

Group type: COMPARATOR
Intervention: Initial conservative management with GDMT alone and angiography reserved for failure of medical therapy
Number of subjects: 5956

Group type: EXPERIMENTAL
Intervention: Long-term follow-up of surviving participants from ISCHEMIA and ISCHEMIA-CKD trials
Number of subjects: 5956
Study: 33797063

Group type: EXPERIMENTAL
Intervention: Bafiertam™ (MMF) 190 mg as 2 × 95 mg delayed-release capsules
Number of subjects: 50

Group type: COMPARATOR
Intervention: Tecfidera® (DMF) 240 mg as 1 × 240 mg delayed-release capsule
Number of subjects: 50
Study: 33051441

Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo (vitamin C)
Number of subjects: 127
Study: 34350569

Group type: EXPERIMENTAL
Intervention: Potassium (K) at 11.6 mmol L‐1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cadmium (Cd) at 1.5 mmol L‐1
Number of subjects: 0
Study: 33785077

Group type: EXPERIMENTAL
Intervention: Exergaming (stepping exergame program, 8 weeks, 3 times weekly, 15 min per session)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (watching preferred music videos)
Number of subjects: 45
Study: 32315295

Group type: EXPERIMENTAL
Intervention: Letrozole monotherapy in real-world cohort
Number of subjects: 107

Group type: COMPARATOR
Intervention: Letrozole 2.5 mg/d in PALOMA-2 trial cohort
Number of subjects: 107
Study: 35266375

Group type: EXPERIMENTAL
Intervention: 600 mg oral gabapentin
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 35279906

Group type: EXPERIMENTAL
Intervention: ET CO2 = 40 mmHg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: ET CO2 = 35 mmHg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: ET CO2 = 45 mmHg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 64
Study: 35696263

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (8-week diet-induced rapid weight loss followed by 148-week lifestyle-based weight maintenance)
Number of subjects: 1510

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 1510
Study: 33879597

Group type: EXPERIMENTAL
Intervention: SMA neurofeedback facilitation using fNIRS (6 sessions)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sham (placebo) intervention
Number of subjects: 54
Study: 33112722

Group type: EXPERIMENTAL
Intervention: FW-squat
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: FW-deadlift
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control
Number of subjects: 15
Study: 33999472

Group type: EXPERIMENTAL
Intervention: Tip-modified curve (group T)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard curve (group S)
Number of subjects: 120
Study: 32502940

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NaCT)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Neoadjuvant endocrine therapy (NET)
Number of subjects: 217
Study: 35834251

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin plus fluocinolone
Number of subjects: 493

Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 493

Group type: COMPARATOR
Intervention: Fluocinolone
Number of subjects: 493
Study: 34702296

Group type: EXPERIMENTAL
Intervention: New predictive equation A based on anthropometric parameters
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: New predictive equation B based on BIA-derived raw variables
Number of subjects: 126

Group type: COMPARATOR
Intervention: Existing equations from literature
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Selected equations (6 out of 8)
Number of subjects: 126
Study: 32935171

Group type: EXPERIMENTAL
Intervention: High-intensity resistance and impact training (HiRIT)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Machine-based isometric axial compression (IAC)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 93
Study: 32598657

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Standard primary PCI without RIPC
Number of subjects: 173
Study: 35435497

Group type: EXPERIMENTAL
Intervention: [18F]FDG‐PET/CT
Number of subjects: 132

Group type: COMPARATOR
Intervention: Diagnostic surgery
Number of subjects: 132
Study: 34016545

Group type: EXPERIMENTAL
Intervention: Experienced Readers (ER)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Novice Readers (NR)
Number of subjects: 32
Study: 32589978

Group type: EXPERIMENTAL
Intervention: Hyper-CVAD regimen plus ofatumumab
Number of subjects: 69
Study: 35536764

Group type: EXPERIMENTAL
Intervention: Febuxostat (40 or 80 mg, based on sUA at Week 2)
Number of subjects: 6190

Group type: COMPARATOR
Intervention: Allopurinol (dose titrated in 100 mg increments from 200-400 mg or 300-600 mg, based on kidney function)
Number of subjects: 6190

Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 6190

Group type: COMPARATOR
Intervention: Allopurinol
Number of subjects: 6190

Group type: EXPERIMENTAL
Intervention: Febuxostat and Allopurinol
Number of subjects: 6190
Study: 34174917

Group type: EXPERIMENTAL
Intervention: Implementation support program for intervention sites including face-to-face events and on-demand components over 12 months.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control sites with no implementation support.
Number of subjects: 20
Study: 32414381

Group type: EXPERIMENTAL
Intervention: Healthy Lifestyles (HL) intervention
Number of subjects: 553

Group type: COMPARATOR
Intervention: Healthy Finances (HF) control
Number of subjects: 553
Study: 32105001

Group type: EXPERIMENTAL
Intervention: Conventional phototherapy (Group I)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intensive phototherapy (Group II)
Number of subjects: 40
Study: 34622721

Group type: EXPERIMENTAL
Intervention: Propolis (250 mg/two times per day for three months)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 33860579

Group type: EXPERIMENTAL
Intervention: Taxane/platinum therapy (paclitaxel + carboplatin)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Taxane/platinum therapy (paclitaxel + carboplatin) with additional docetaxel and nedaplatin
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Taxane/platinum therapy
Number of subjects: 165
Study: 36163925

Group type: EXPERIMENTAL
Intervention: asciminib 40 mg twice daily
Number of subjects: 233

Group type: COMPARATOR
Intervention: bosutinib 500 mg once daily
Number of subjects: 233
Study: 34023360

Group type: EXPERIMENTAL
Intervention: ProTaper Universal (PTU)
Number of subjects: 180

Group type: COMPARATOR
Intervention: ProTaper Gold (PTG)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Twisted File Adaptive (TFA)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Reciproc Blue (RB)
Number of subjects: 180
Study: 33074552

Group type: EXPERIMENTAL
Intervention: Fetoscopic endoluminal tracheal occlusion (FETO)
Number of subjects: 311
Study: 32492087

Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg/d
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg/d
Number of subjects: 391

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 391
Study: 35691323

Group type: EXPERIMENTAL
Intervention: Ustekinumab (6 mg/kg IV on day 0, then 90 mg SC every 8 weeks)
Number of subjects: 386

Group type: COMPARATOR
Intervention: Adalimumab (160 mg on day 0, 80 mg at 2 weeks, then 40 mg SC every 2 weeks)
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 386

Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 386
Study: 34255718

Group type: EXPERIMENTAL
Intervention: Project EMPOWER (self-guided single-session intervention)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Informational control (psychoeducational materials and resources)
Number of subjects: 301
Study: 36008759

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 μg/kg over 10 min (group D1)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 μg/kg/h continuous infusion (group D2)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg/kg over 10 min and 0.5 μg/kg/h continuous infusion (group D3)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (normal saline) (group C)
Number of subjects: 81
Study: 32000820

Group type: EXPERIMENTAL
Intervention: Oral dydrogesterone 10 mg three times daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36337054

Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT)
Number of subjects: 247
Study: 33630863

Group type: EXPERIMENTAL
Intervention: Stockholm3 Model (S3M) test as a reflex test for PSA ≥ 2 ng/mL
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stockholm3 Model (S3M) test with reflex thresholds of 1 ng/mL
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stockholm3 Model (S3M) test with reflex thresholds of 1.5 ng/mL
Number of subjects: 0

Group type: COMPARATOR
Intervention: PSA test alone
Number of subjects: 0
Study: 34816601

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET) pretreatment to Dialectical Behaviour Therapy Skills Training (DBT-ST); 4-week group MET pretreatment followed by 12-week DBT-ST
Number of subjects: 45

Group type: COMPARATOR
Intervention: Dialectical Behaviour Therapy Skills Training (DBT-ST) only; 12-week DBT-ST
Number of subjects: 45
Study: 33651341

Group type: EXPERIMENTAL
Intervention: SDZ-ADL
Number of subjects: 818